Dermatological toxicity of EGFR inhibitors: pathogenetic rationale and an algorithm for acne-like rash correction-Reference-Cited by-同舟云学术

Dermatological toxicity of EGFR inhibitors: pathogenetic rationale and an algorithm for acne-like rash correction

Published:2021-11-11 Issue:4 Volume:16 Page:50-58
ISSN:2413-4023
Container-title:Oncohematology
language:
Short-container-title:Onkogematologiâ

Author:

Michenko A. V.¹^ORCID,Kruglova L. S.¹^ORCID,Shatokhina E. A.¹^ORCID,Kononenko I. B.²^ORCID,Polonskaya A. S.¹^ORCID,Romanov D. V.³^ORCID

Affiliation:

1. Central State Medical Academy, Administrative Directorate of the President of the Russian Federation

2. N.A. Lopatkin Research Institute of Urology and Interventional Radiology – branch of the National Medical Research Radiological Center, Ministry of Health of Russia

3. I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University); Mental Health Research Center

Abstract

Therapy with epidermal growth factor receptor (EGFR) inhibitors is inevitably accompanied by the phenomena of dermatological toxicity. Being, on the one hand, a favorable prognostic factor for the effectiveness of anticancer therapy, these adverse events are one of the most frequent indications for treatment withdrawal. This article presents the clinical characteristics of a wide spectrum of dermatological adverse events, as well as the pathogenetic rationale for their correction. Algorithms for prescribing of external and systemic therapy based on the assessment of severity of skin lesions and skin appendages involvement are presented.

Publisher

Publishing House ABV Press

Subject

Oncology,Hematology

Reference16 articles.

1. Chanprapaph K., Vachiramon V., Rattanakaemakorn P. Epidermal growth factor receptor inhibitors: a review of cutaneous adverse events and management. Dermatol Res Pract 2014;2014:734249. DOI: 10.1155/2014/734249.

2. Lacouture M.E. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006;6(10):803–12. DOI: 10.1038/nrc1970.

3. Pérez-Soler R., Delord J.P., Halpern A. et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 2005;10(5):345–56. DOI: 10.1634/theoncologist.10-5-345.

4. Pérez-Soler R., Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? Clin Oncol 2005;23(22):5235–46. DOI: 10.1200/JCO.2005.00.6916.

5. Palmer C.N., Irvine A.D., Terron-Kwiatkowski A. et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006;38(4):441–6. DOI: 10.1038/ng1767.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Skin microbiome in cancer patients with pruritus and other skin toxic reactions related to anticancer therapy: A review;Consilium Medicum;2023-11-05

2. Xerosis of skin on background of anticancer therapy: Literature review and own experience with use of dermatocosmetics;Medical alphabet;2023-05-01

3. Pruritus in cancer patients as a polyetiological symptom;Consilium Medicum;2022-11-02

4. Balneotherapy as a promising method for the correction of dermatologic adverse events of cancer therapy;Russian Journal of Physiotherapy, Balneology and Rehabilitation;2022-09-15